SI-BONE To Report First Quarter 2022 Financial Results on May 9, 2022

Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN) will report its Q1 2022 financial results on May 9, 2022, after market close. A conference call will follow at 1:30 p.m. PT, with access for investors via phone or webcast. As a leader in surgical treatment for sacropelvic disorders, SI-BONE's iFuse Implant System has facilitated over 65,000 SI joint fusion procedures, supported by extensive clinical evidence and insurance coverage. The company continues to leverage its market position to develop additional surgical devices.

Positive

• Market leader in sacropelvic disorder treatment.
• Over 65,000 SI joint fusion procedures performed.
• Strong clinical evidence supporting the iFuse Implant System.

Negative

• None.

SANTA CLARA, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2022 after market close on Monday, May 9, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 6088498. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of chronic low back pain. Since then, more than 2,700 surgeons have performed a combined total of more than 65,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two RCT’s and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System. SI-BONE is leveraging its market leadership position, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related aspects of the human anatomy. For more information or to join our team, please visit us at www.si-bone.com.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2022 SI-BONE, Inc. All Rights Reserved.

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com 

Media Contact:
Joe Powers
jpowers@si-bone.com 

FAQ

When will SI-BONE report its Q1 2022 financial results?

SI-BONE will report its Q1 2022 financial results on May 9, 2022, after market close.

What time is the SI-BONE conference call?

The conference call will begin at 1:30 p.m. Pacific Time on May 9, 2022.

How can I listen to the SI-BONE conference call?

Investors can listen to the conference call by dialing (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 6088498.

What is the significance of the iFuse Implant System?

The iFuse Implant System is a minimally invasive surgical device for SI joint fusion, with over 65,000 procedures performed and strong clinical support.